Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.40 |
| ▸ | HTR2C | P28335 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619067 | 0.90 | HTR2A (0.40) | HTR2AHTR2CNPC1RAB9APKM | |
| SCHEMBL29619066 | 0.90 | HTR2A (0.40) | HTR2AHTR2CNPC1RAB9APKM | |
| SCHEMBL31677725 | 0.88 | WNT3A (0.46) | HTR2AHTR2CKCNH2WNT3AFLT3 | |
| SCHEMBL31677761 | 0.86 | HTR2A (0.41) | HTR2AHTR2CNPC1RAB9AWNT3A | |
| SCHEMBL31677759 | 0.84 | FLT3 (0.42) | HTR2AHTR2CWNT3AFLT3 | |
| SCHEMBL31678111 | 0.81 | HTR2A (0.57) | HTR2AHTR2C | |
| SCHEMBL31677751 | 0.81 | HTR2A (0.59) | HTR2AHTR2C | |
| SCHEMBL31678112 | 0.80 | HTR2A (0.61) | HTR2AHTR2CKCNH2 | |
| SCHEMBL31677911 | 0.78 | ESR1 (0.37) | KCNH2WNT3AFLT3 | |
| SCHEMBL29619114 | 0.78 | WNT3A (0.44) | HTR2AHTR2CKCNH2WNT3AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 4/4885NPC1 2828/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | HTR2A 3/4885HTR2C 1/4885NPC1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.